Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech)

N/A

Report date: 2024/12/19 14:58:49

Base Information

Drug NameAnti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech)

Drug Alias NameLCAR-L10D

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesNanjing Legend Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNanjing Legend Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A